Test your knowledge HR-positive, HER2- Breast Cancer

What is the age-adjusted rate of new cases of HR+ HER2- breast cancer per 100,000 women, based on data from 2017 to 2021?
50.2 per 100,000 women
73.2 per 100,000 women
90.1 per 100,000 women
120.4 per 100,000 women
In 2022, Black women were how much more likely to be diagnosed with HR+ HER2- breast cancer compared to other women?
Equally likely
1.5 times as likely
Twice as likely
Three times as likely
How does the prognosis of HR+ HER2- breast cancer compare to HER2+ or triple-negative breast cancer?
Worse prognosis due to resistance to endocrine therapy
Better prognosis due to targeted therapy options
Similar prognosis depending on tumor stage and grade
Better prognosis due to slower growth rate
Which of the following is a targeted therapy specifically used in HR+ HER2- breast cancer?
Trastuzumab
Pertuzumab
Palbociclib
Cetuximab
When administering CDK4/6 inhibitors such as palbociclib and ribociclib for the treatment of HR+ HER2- breast cancer, which of the following adverse events is most frequently observed?
Neutropenia
Fatigue
Diarrhea
Hyperglycemia
Abemaciclib is another targeted therapy approved for HR+, HER2- breast cancer. What is its mechanism of action?
Inhibition of cyclin-dependent kinases 4 and 6 (CDK4/6)
Inhibition of HER2 signaling
Blockade of estrogen receptors
Stimulation of apoptosis
In the treatment for HR+, HER2- breast cancer with CDK4/6 inhibitors like abemaciclib, which of the following adverse events is most commonly observed and may require dose adjustment or supportive care?
Hypertension
Diarrhea
Hyperglycemia
Alopecia
The MonarchE trial investigated the efficacy of abemaciclib in combination with endocrine therapy in patients with high-risk, early-stage breast cancer. Which of the following statements is true regarding dose reductions for patients experiencing adverse events during this trial?
Dose reduction is not recommended; patients should discontinue treatment if they experience severe adverse events
Dose reduction should only be considered after three occurrences of the same adverse event
Dose reduction is recommended to manage adverse events, with specific guidelines provided for adjusting the dose of abemaciclib
Patients should automatically have their dose reduced by 50% at the first sign of any adverse event
What is the first-line treatment approach for a postmenopausal woman diagnosed with HR+ HER2- breast cancer?
Chemotherapy
Trastuzumab
Hormone therapy +/- CDK4/6 inhibitor
Radiation therapy
Is the treatment for men with HR+ HER2- breast cancer different from the treatment for women with the same type of breast cancer?
Yes, men receive a completely different treatment regimen
No, the treatment is generally the same for both men and women
Men only receive surgical treatment, while women receive medication
Men receive more aggressive treatment than women
Which of these is usually used to confirm HR and HER2 status?
Blood workup
Immunohistochemistry staining
MRI
CT
Which of these has been shown to be the most common site of metastasis?
Bone
Liver
Spleen
Brain
{"name":"Test your knowledge HR-positive, HER2- Breast Cancer", "url":"https://www.poll-maker.com/QWHL90U9K","txt":"What is the age-adjusted rate of new cases of HR+ HER2- breast cancer per 100,000 women, based on data from 2017 to 2021?, In 2022, Black women were how much more likely to be diagnosed with HR+ HER2- breast cancer compared to other women?, How does the prognosis of HR+ HER2- breast cancer compare to HER2+ or triple-negative breast cancer?","img":"https://www.poll-maker.com/3012/images/ogquiz.png"}
Tools: Poll Maker | Quiz Maker | Super Surveys